Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.780
+0.2000.63%
Volume:7.10M
Turnover:226.24M
Market Cap:192.71B
PE:29.29
High:32.300
Open:31.800
Low:31.500
Close:31.580
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:0.62
T/O Rate:0.12%
Dividend:0.43
Dividend Rate:1.36%
EPS(LYR):1.085
ROE:17.35%
ROA:9.44%
PB:4.67
PE(LYR):29.29
PS:10.99

Loading ...

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10582 Tablets Issued By- National Medical Products Administration

THOMSON REUTERS
·
Aug 06

Hansoh Pharma Sets 26 Aug 2026 Board Meeting to Review 1H26 Results and Interim Dividend

Bulletin Express
·
Aug 04

HANSOH PHARMA July 2026 Share Capital Update: No Change in Issued Shares; HKD 4.68 Billion Convertibles Outstanding

Bulletin Express
·
Aug 04

Hansoh Pharmaceutical Group Stock Slides 2.1% in Hong Kong

Dow Jones
·
Aug 03

Movement Alert|HANSOH PHARMA Declines 3.05% in Regular Trading, Trading at 31.16 HKD

Market Focus
·
Aug 03

Movement Alert|HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure

Market Focus
·
Jul 30

Hansoh Pharmaceutical Group Stock Rallies 3.7% in Hong Kong

Dow Jones
·
Jul 29

Offshore Wind Tendering Heats Up in July as ASMPT Posts Strong Interim Profit Jump

Stock News
·
Jul 29

GSK Q2 Sales Beat Analyst Estimates on Specialty Medicines Growth

Reuters
·
Jul 28

GSK, Hansoh's Cancer Drug Meets Main Goal of Bone Cancer Trial

Reuters
·
Jul 28

Hansoh Pharma's HS-20093 Achieves Primary Goal in Phase III Osteosarcoma Study

Stock News
·
Jul 28

Hansoh Pharma Says Artemis-011 Phase 3 Trial of Hs-20093 Meets Primary PFS Endpoint in Osteosarcoma

Reuters
·
Jul 28

Hansoh Pharmaceutical - to Initiate Biologics License Application Process in China in the Near Term

THOMSON REUTERS
·
Jul 28

Hansoh Pharmaceutical - Phase Iii Clinical Study of Hs-20093 in Treatment- of Osteosarcoma Has Met Primary Endpoint

THOMSON REUTERS
·
Jul 28

CLSA Maintains Positive Rating on Hansoh Pharma, Raises Price Target to HK$42

Deep News
·
Jul 28

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.24 From HK$38, Keeps at Neutral

MT Newswires Live
·
Jul 27

Oral Cyclic Peptides Enter Validation Phase, Opening a Multi-Billion Dollar Therapeutic Arena

Stock News
·
Jul 22

Hansoh Pharmaceutical Group Stock Slips 1.5% in Hong Kong

Dow Jones
·
Jul 21

Movement Alert|Hansoh Pharmaceutical Declines 3.33% in Regular Trading, Trading at HK$31.98

Market Focus
·
Jul 21

Hansoh Pharmaceutical Group Stock Rises 4.0% in Hong Kong

Dow Jones
·
Jul 20